Curatis: Deutsche Gesteigerter Umsatz im Kerngeschäft und Projekte in der Entwicklungspipeline on Kurs Seite 1

Curatis Holding (SIX:CURN) has earned CHF 2.0 million for the first half of 2024, while Curatis AG has now ended 2 months. Curatis AG was able to increase its turnover in the 6 months of 2024 by 31% percent to CHF 4.3 million. The loss amounted to CHF 3.8 million. No liquidity transactions are possible and depreciation is not a transaction cost for the company of Curatis AG. The cash flow, ultimately one-off transaction costs for the corporate merger of over CHF 1 million, amounted to CHF -0.7 million. Who plans how orphan drug status will be granted to the lead product candidate C-PBTE-01 at the US Food and Drug Administration (FDA) and will be processed by the FDA in four quarters of 2024.

Geschäftsentwicklung und Financing